MALT lymphoma · 5 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cladribine and Rituximab Variant #01 | — | R 33 968 | 21d | — | — | — | — | — |
Bortezomib monotherapy Variant #14 | — | R 8 539 | 35d | ~30.3 mo | — | ~27 | ~R 230 565 PFS proxy · indirect | 5 |
Lenalidomide monotherapy N/A - secondary systemic drug | — | R 6 361 | 90d | ~30.8 mo | — | ~11 | ~R 69 973 PFS proxy · indirect | 2 |
Clarithromycin monotherapy Variant #01 | — | R 382 | 21d | — | — | — | — | — |
Rituximab monotherapy N/A - secondary systemic drug | — | R 52 | 180d | ~20.3 mo | — | ~4 | ~R 208 PFS proxy · indirect | 17 |
5 of 5 regimens shown